Search the database for deliberate release of GM medicinal products
Displaying 1 - 6 of 6
|EU record number
|Company / Sponsor
|Dossier withdrawn by the notifier
|V181 is a live attenuated dengue quadrivalent vaccine rDENVΔ30 where the four viral components of V181 (one for each serotype) present a deletion of 30 nucleotides in the 3’ non‐coding region (Δ30)
|Only notified under the "contained use" procedure. Dossier submitted on 07/04/2014.
|A single-center, open-label Phase 1 study to assess safety and medical endoscopic sampling methodology and to characterize the pharmacokinetics of oral doses of AG014 in Healthy Subjects
|gene expressing certolizumab
|Only notified under the "contained use" procedure. Dossier submitted on 08/05/2012.
|A single-center, open-label Phase 1 study to assess the effect of food/beverage and to characterisze the pharmacokinetics of single and multiple oral doses of AG013 in Healthy Subjects
|Human Trefoil Factor 1
|Only notified under the "contained use" procedure. Dossier submitted on 23/04/2012.
|Randomized Phase III of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
|-Thymidine Kinase (HSV-Tk) - selection marker
|Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
|Pfizer, Animal Health Group
|gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
|Only notified under the "contained use" procedure. Dossier submitted on 11/07/2002.
|A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina